ArticleCell communication and signaling : CCS2025
CLIP2: a novel functional player in AQP5 trafficking dynamics and implications for Sjögren's disease.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundSjögren's disease (SjD) is an autoimmune condition affecting exocrine glands, resulting in decreased saliva and tear production. Aquaporin 5 (AQP5) is a transmembrane water channel playing a central role in water transport. In SjD, deregulation of AQP5 expression, trafficking and interactions with various proteins contribute to the underlying disease mechanisms.
methodsCo-immunoprecipitation followed by mass spectrometry, proximity ligation assay, microscale thermophoresis and in-silico modelling were carried out to investigate protein-protein interaction. CRISPR/Cas9-mediated knockout was performed in a salivary gland cell line stably transfected with AQP5. Protein colocalization and AQP5 trafficking were studied by immunofluorescence. Autoantibodies were quantified by ELISA.
resultsWe identified CAP-Gly Domain Containing Linker Protein 2 (CLIP2) as a novel AQP5-interacting partner. Structural modeling of the AQP5-CLIP2 interaction revealed that the interaction is similar to other CAP-Gly domain complexes. Functional investigations indicated CLIP2 significantly influences AQP5 trafficking to the plasma membrane. Furthermore, interactions of CLIP2 with other AQP5 partners reveal the possible formation of multiprotein complexes in salivary glands. In SjD patients, alterations in these complexes and the presence of autoantibodies against AQP5, CLIP2, and other AQP5-interacting partners such as Ezrin and prolactin-inducible protein (PIP) may also contribute to disease pathogenesis.
conclusionOur study identifies CLIP2 as a novel player in the AQP5 interactome and sheds light on its crucial role in AQP5 trafficking. In SjD, the alterations in AQP5-CLIP2 interactions and the presence of autoantibodies against both proteins highlighted their potential as targets for future therapeutic interventions in SjD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.